Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis.

Published on Mar 1, 2017in Gut19.819
· DOI :10.1136/GUTJNL-2016-312049
Atsushi Masamune67
Estimated H-index: 67
(Tohoku University),
Isao Nishimori55
Estimated H-index: 55
+ 26 AuthorsTooru Shimosegawa28
Estimated H-index: 28
(Tohoku University)
Sources
Abstract
Objective Corticosteroid has been established as the standard therapy for autoimmune pancreatitis (AIP), but the requirement for maintenance corticosteroid therapy is controversial. We conducted a randomised controlled trial to clarify the efficacy of maintenance corticosteroid therapy in patients with AIP. Design We conducted a multicentre, tertiary setting, randomised controlled trial. After the induction of remission with the initial oral prednisolone (PSL) treatment, maintenance therapy with PSL at 5–7.5 mg/day was continued for 3 years or withdrawn at 26 weeks. The primary endpoint was relapse-free survival over 3 years and the secondary endpoint was serious corticosteroid-related complications. All analyses were performed on an intention-to-treat basis. Results Between April 2009 and March 2012, 49 patients with AIP were randomly assigned to the maintenance therapy group (n=30) or the cessation group (n=19). Baseline characteristics were not different between the two groups. Relapses occurred within 3 years in 11 out of 19 (57.9%) patients assigned to the cessation group, and in 7 of 30 (23.3%) patients in the maintenance therapy group. The relapse rate over 3 years was significantly lower in the maintenance therapy group than that in the cessation group (p=0.011). The relapse-free survival was significantly longer in the maintenance therapy group than that in the cessation group (p=0.007). No serious corticosteroid-related complications requiring discontinuation of PSL were observed. Conclusions Maintenance corticosteroid therapy for 3 years may decrease relapses in patients with AIP compared with those who discontinued the therapy at 26 weeks. Trial registration number UMIN000001818; Results.
📖 Papers frequently viewed together
20112.92Pancreas
14 Authors (Tooru Shimosegawa, ..., Lizhi Zhang)
948 Citations
200919.82Gut
19 Authors (Terumi Kamisawa, ..., Masao Omata)
516 Citations
201319.82Gut
14 Authors (Phil A. Hart, ..., Suresh T. Chari)
254 Citations
References30
Newest
#1Kenji Hirano (UTokyo: University of Tokyo)H-Index: 46
#2Minoru TadaH-Index: 60
Last. Kazuhiko KoikeH-Index: 91
view all 20 authors...
To predict the duration of steroid maintenance therapy required to achieve good prognosis in patients with autoimmune pancreatitis.The study sample comprised 21 patients with autoimmune pancreatitis who met the following criteria: (1) they received steroid therapy (ST) for at least 3 years without clinical relapse; and (2) immunoglobulin (Ig) G 1600 mg/dL.During the 43-month (range, 19 to 48 mo) follow-up period, clinical relapse occurred in 10 patients: pancreatic lesion in 4; coronary lesion i...
20 CitationsSource
#1Kazuichi Okazaki (Kansai Medical University)H-Index: 85
#2Kazushige UchidaH-Index: 30
Before the immunoglobulin G4 (IgG4) era, autoimmune pancreatitis was proposed as a single clinical entity of autoimmune disease. In the IgG4 era, the following 2 subtypes have been proposed: type 1 is the pancreatic manifestation of IgG4-related disease and type 2 presents with granulocytic epithelial lesions. The characteristic features of type 1 are increased serum IgG4, lymphoplasmacytic sclerosing pancreatitis (abundant infiltration of IgG4+ plasmacytes and lymphocytes, storiform fibrosis, a...
24 CitationsSource
#1Shuya Shimizu (Nagoya City University)H-Index: 13
#2Itaru Naitoh (Nagoya City University)H-Index: 22
Last. Takashi Joh (Nagoya City University)H-Index: 69
view all 17 authors...
AbstractObjectives. Autoimmune pancreatitis (AIP) responds well to corticosteroid therapy (CST), and CST is essential to induce remission. However, the correlation between long-term outcome and CST has not been evaluated. We aimed to clarify the correlation between long-term outcome of AIP and CST. Material and methods. We retrospectively evaluated relapse, risk of malignancy and side effects of CST by focusing on the correlation with CST in 84 patients with type 1 AIP. Results. The incidence of...
17 CitationsSource
#1Atsushi Kanno (Kansai Medical University)H-Index: 39
#1Atsushi Kanno (Kansai Medical University)H-Index: 18
Last. Tooru ShimosegawaH-Index: 28
view all 8 authors...
OBJECTIVES: To clarify the clinicoepidemiological features of autoimmune pancreatitis (AIP) in Japan, a nationwide epidemiological survey was conducted. METHODS: Patients with AIP who had visited selected hospitals in 2011 were surveyed. Autoimmune pancreatitis was diagnosed according to the revised clinical diagnostic criteria for AIP (Japan Pancreas Society 2011). The study consisted of 2 stage surveys; the number of patients with AIP was estimated by the first questionnaire, and their clinica...
91 CitationsSource
#1Terumi KamisawaH-Index: 77
#2Yoh Zen (Kobe University)H-Index: 87
Last. John H. Stone (Harvard University)H-Index: 94
view all 4 authors...
Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is an immune-mediated condition that can affect almost any organ and is now being recognized with increasing frequency. IgG4-RD is characterized by a lymphoplasmacytic infiltrate composed of IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis, and mild to moderate eosinophilia. The diagnosis of IgG4-RD unifies many eponymous fibroinflammatory conditions that had previously been thought to be confined to single organs. IgG4-RD lesions ...
621 CitationsSource
#1Matthew T. Huggett (UCL: University College London)H-Index: 6
#2Emma L. Culver (John Radcliffe Hospital)H-Index: 17
Last. Eleanor BarnesH-Index: 57
view all 11 authors...
Type 1 Autoimmune Pancreatitis and IgG4-Related Sclerosing Cholangitis Is Associated With Extrapancreatic Organ Failure, Malignancy, and Mortality in a Prospective UK Cohort
145 CitationsSource
#1Phil A. Hart (Mayo Clinic)H-Index: 29
#2Ryan J. Law (Mayo Clinic)H-Index: 2
Last. Suresh T. ChariH-Index: 103
view all 6 authors...
ObjectivesThe risk of pancreatic and extrapancreatic cancer in autoimmune pancreatitis (AIP) has not been systematically evaluated. We compared the risk of malignancy in AIP patients and matched control subjects.MethodsWe identified 116 subjects with AIP from a prospectively maintained database. Fro
60 CitationsSource
#1Terumi Kamisawa (Tokyo Metropolitan Komagome Hospital)H-Index: 77
#2Kazuichi Okazaki (Kansai Medical University)H-Index: 85
Last. Tooru Shimosegawa (Tohoku University)H-Index: 28
view all 15 authors...
Background In response to the proposal of the international consensus diagnostic criteria (ICDC) for autoimmune pancreatitis (AIP) and the Japanese diagnostic criteria in 2011, the 2009 Japanese consensus guidelines for managing AIP required revision.
154 CitationsSource
#1Phil A. Hart (Mayo Clinic)H-Index: 29
#2Terumi Kamisawa (Tokyo Metropolitan Komagome Hospital)H-Index: 77
Last. Suresh T. Chari (Mayo Clinic)H-Index: 103
view all 25 authors...
Objective Autoimmune pancreatitis (AIP) is a treatable form of chronic pancreatitis that has been increasingly recognised over the last decade. We set out to better understand the current burden of AIP at several academic institutions diagnosed using the International Consensus Diagnostic Criteria, and to describe long-term outcomes, including organs involved, treatments, relapse frequency and long-term sequelae. Design 23 institutions from 10 different countries participated in this multination...
343 CitationsSource
#1Phil A. Hart (Mayo Clinic)H-Index: 29
#2Mark Topazian (Mayo Clinic)H-Index: 65
Last. Suresh T. Chari (Mayo Clinic)H-Index: 103
view all 14 authors...
Background There is a paucity of data on long-term management of type 1 autoimmune pancreatitis (AIP), a relapsing steroid-responsive disorder. Objective We describe our experience with treatment of relapses and maintenance of remission using steroid-sparing immunomodulators (IMs) and induction of remission using rituximab (RTX). Methods We obtained details of disease relapse and treatment in 116 type 1 AIP patients from clinic visits, medical records and telephone interviews. We compared relaps...
254 CitationsSource
Cited By88
Newest
#1Yoshiharu Masaki (Sapporo Medical University)H-Index: 7
#2Hiroshi Nakase (Sapporo Medical University)H-Index: 48
Last. Yuzo Kodama (Kobe University)H-Index: 35
view all 0 authors...
The effectiveness of azathioprine (AZA) in preventing relapse and maintaining autoimmune pancreatitis (AIP) remission has been reported; however, most of these studies are case series with no randomized control trials available in the literature. Therefore, this study performed a systematic review and meta-analysis of the existing literature on this subject to determine the clinical efficacy of AZA as maintenance therapy for AIP patients. A systematic search was performed to identify studies on ...
Source
Retroperitoneal fibrosis (RPF) is a rare disorder consisting of idiopathic and various secondary forms and characterized by chronic inflammatory infiltrates and marked fibrosis in the retroperitoneal space. In idiopathic RPF (IRPF), 35-60% of cases have been reported to be IgG4-related RPF, the retroperitoneal lesions of IgG4-related disease (IgG4-RD). IRPF can frequently lead to renal insufficiency mediated by urinary tract obstruction and hydronephrosis irrespective of being IgG4-related or no...
Source
#1Gabrielle Brody (UCI: University of California, Irvine)
#2Michael O. Nguyen (UCI: University of California, Irvine)
Last. Bonnie A. Lee (UCI: University of California, Irvine)H-Index: 4
view all 4 authors...
Source
#1Hossein Haghbin (UT: University of Toledo)H-Index: 4
#2Justin Chuang (UT: University of Toledo)
Last. Muhammad Aziz (UT: University of Toledo)H-Index: 13
view all 6 authors...
Background null There is conflicting evidence regarding autoimmune pancreatitis (AIP) association with pancreatic and non-pancreatic cancers. Literature lacks data on overall prevalence of malignancies in autoimmune pancreatitis. null Aim null Given the lack of definite evidence, we aimed to pool and summarize data from available literature regarding prevalence of different malignancies in AIP. null Methods null We conducted a systematic search of MEDLINE, EMBASE, Cochrane Register of Controlled...
Source
Last. Kam A. Newman (UCR: University of California, Riverside)H-Index: 9
view all 5 authors...
Source
#1Sushil K. GargH-Index: 5
#1Sushil Kumar GargH-Index: 23
Last. Suresh T. ChariH-Index: 103
view all 2 authors...
Source
#1Yasuki Hori (Nagoya City University)H-Index: 13
#2Suresh T. Chari (Mayo Clinic)H-Index: 103
Last. Akira Satou (Aichi Medical University)H-Index: 8
view all 14 authors...
Biliary strictures caused by inflammation or fibrosis lead to jaundice and cholangitis which often make it difficult to distinguish malignant strictures. In cases when malignancy cannot be excluded, surgery is often performed. The concept of immunoglobulin G4 (IgG4)-related sclerosing cholangitis (SC) as a benign biliary stricture was recently proposed. The high prevalence of the disease in Asian countries has resulted in multiple diagnostic and treatment guidelines; however, there is need to fo...
Source
#1Seung Bae Yoon (Catholic University of Korea)H-Index: 10
#2Sung-Hoon Moon (Hallym University)H-Index: 8
Last. Myung-Hwan Kim (UOU: University of Ulsan)H-Index: 89
view all 6 authors...
Abstract null null Background null The indications for maintenance glucocorticoid therapy (MGT) and its duration after initial remission of type 1 autoimmune pancreatitis (AIP) remain controversial. In contrast to the Japanese treatment protocol, the Mayo protocol does not recommend MGT after initial remission. This study aimed to evaluate the relapse rate in patients with type 1 AIP according to the duration of glucocorticoid therapy. null null null Methods null We conducted a systematic litera...
1 CitationsSource
#1Masataka Yokode (Kyoto University)H-Index: 1
#1Masataka Yokode (Kyoto University)H-Index: 2
Last. Yuzo Kodama (Kobe University)H-Index: 35
view all 3 authors...
Autoimmune pancreatitis (AIP) is a pancreatic manifestation of an IgG4-related disease (IgG4-RD). AIP lacks disease-specific biomarkers, and therefore, it is difficult to distinguish AIP from malignancies, especially pancreatic cancer. In this review, we have summarized the latest findings on potential diagnostic biomarkers for AIP. Many investigations have been conducted, but no specific biomarkers for AIP are identified. Therefore, further studies are required to identify accurate diagnostic b...
1 CitationsSource
#1Ayami Fukiage (Hiroshima University)H-Index: 2
#2Hatsue Fujino (Hiroshima University)H-Index: 14
Last. Kazuaki Chayama (Hiroshima University)H-Index: 124
view all 10 authors...
BACKGROUND: Serum IgG4 level is a useful diagnostic marker for autoimmune pancreatitis (AIP), but it is difficult to use to predict relapse. AIMS: We investigated whether serum autotaxin (ATX) level is predictive of AIP relapse after steroid therapy. METHODS: Fifty-six patients with type 1 AIP were investigated. We measured serum ATX at the time of diagnosis. We selected 24 males for whom serum samples during steroid therapy had been obtained and measured serum ATX at steroid therapy for inducti...
2 CitationsSource